On September 2nd, 2023, the China International Trade in Services Fair officially opened in Beijing.

At the trade fair, Hubei Mengyang Pharmaceutical signed a strategic cooperation agreement with TCMG Group in the United States, innovating the overseas model of traditional Chinese medicine, and becoming the first Chinese traditional Chinese medicine pharmaceutical enterprise to initiate the admission process in the mainstream hospital system of the United States with the goal of large-scale clinical promotion and application in the future.

TCMG Group is a world-class commercial service platform for traditional Chinese medicine, with a long-term focus on the clinical application of integrated traditional Chinese and Western medicine, evidence-based medicine clinical research, and medical practitioner training. It promotes the integration of traditional Chinese medicine and Western medicine and is a leader in expanding the clinical practice of integrated traditional Chinese and Western medicine in the US hospital system. The group has an online traditional Chinese medicine service platform and offline hospital terminal channels covering 50 states in the United States, and has leadership and influence in the integrated traditional Chinese and Western medicine industry radiating across the country.

According to the cooperation agreement, Mengyang Pharmaceutical's "Shengbai Oral Liquid" will undergo an IRB approved post market safety re evaluation at Sutter Health Hospital in the United States. Once approved, it can officially enter relevant hospitals in the United States for clinical scale application.

Sutter Health Hospital is a top private hospital group with a 100 year history in the United States. It has 24 hospitals and 200 Western medicine clinics in Northern California, with over 12000 doctors and 16000 caregivers. At the same time, Sutter Health Hospital is also the industry benchmark for exploring the integration of traditional Chinese and Western medicine within the mainstream hospital system in the United States.

"In the process of tumor treatment in mainstream western hospitals in the United States, patients have many appeals to reduce treatment pain and improve the quality of life. In this regard, western medicine has limited methods, while traditional Chinese medicine has an obvious role. We hope to find more new ways to benefit tumor patients through the combination of traditional Chinese medicine and western medicine, which is our original intention to cooperate with Mengyang Pharmaceutical." The former director of the acupuncture and moxibustion Bureau of California, USA, and now a member of the committee of the acupuncture and moxibustion Bureau, Amy Matecki, Director of Integrated Medicine at Sutter Health Hospital's Comprehensive Cancer Center, stated. For a long time, due to the lack of modern evidence-based medicine evidence and the difficulty of traditional Chinese medicine theory being accepted by clinical doctors in mainstream Western hospitals in the United States, most traditional Chinese medicine products can only be circulated in Chinese clinics or private small clinics, with the majority of users being Chinese who can accept traditional Chinese medicine culture.

"This cooperation will provide a replicable successful model and channel breakthrough for the commercialization of innovative traditional Chinese medicine products overseas, helping China's leading pharmaceutical industry with innovative traditional Chinese medicine research and production capabilities to better go abroad and embrace the global market." said Gao Yuan, founder and CEO of TCMG Group.

"Global medical practice has shown that cancer diseases are developing towards a chronic direction, which means patients need to coexist with tumors for a long time. Traditional Chinese medicine has more advantages in helping patients alleviate pain and improve their quality of life during the treatment process, and is becoming an industry consensus. The emergence of this new track in the field of tumor treatment and related diseases makes it easier for traditional Chinese medicine to play a unique role in Western medicine's radiotherapy and chemotherapy processes." Zhang Min, Chairman of Mengyang Pharmaceutical, said, "Traditional Chinese Medicine has a development history of thousands of years. We hope to further leverage the unique advantages and role of traditional Chinese medicine in disease prevention and treatment, enhance its international competitiveness, and enable the treasures of Chinese civilization to serve patients worldwide, contributing the power of traditional Chinese medicine to human health." (End)